| 000 | 01715 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514195139.0 | ||
| 264 | 0 | _c20041110 | |
| 008 | 200411s 0 0 eng d | ||
| 022 | _a0264-410X | ||
| 024 | 7 |
_a10.1016/j.vaccine.2004.01.058 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCooper, C L | |
| 245 | 0 | 0 |
_aSafety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. _h[electronic resource] |
| 260 |
_bVaccine _cAug 2004 |
||
| 300 |
_a3136-43 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xadverse effects |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Viral _xanalysis |
| 650 | 0 | 4 |
_aAntibody Formation _ximmunology |
| 650 | 0 | 4 | _aDose-Response Relationship, Immunologic |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHemagglutinins _xanalysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfluenza Vaccines _xadministration & dosage |
| 650 | 0 | 4 |
_aInterferon-alpha _xanalysis |
| 650 | 0 | 4 |
_aInterferon-gamma _xanalysis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMonocytes _xmetabolism |
| 650 | 0 | 4 |
_aOligodeoxyribonucleotides _xadverse effects |
| 700 | 1 | _aDavis, H L | |
| 700 | 1 | _aMorris, M L | |
| 700 | 1 | _aEfler, S M | |
| 700 | 1 | _aKrieg, A M | |
| 700 | 1 | _aLi, Y | |
| 700 | 1 | _aLaframboise, C | |
| 700 | 1 | _aAl Adhami, M J | |
| 700 | 1 | _aKhaliq, Y | |
| 700 | 1 | _aSeguin, I | |
| 700 | 1 | _aCameron, D W | |
| 773 | 0 |
_tVaccine _gvol. 22 _gno. 23-24 _gp. 3136-43 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.vaccine.2004.01.058 _zAvailable from publisher's website |
| 999 |
_c14996924 _d14996924 |
||